SCHEMBL21797968

SCHEMBL21797968

CC(C)(CCCCl)C(=O)N1N=CCC1c1cncc(F)c1

nearest known ligand 0.54

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 20/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21797964 0.89 RIPK1 (0.68) RIPK1
SCHEMBL24018703 0.89 RIPK1 (0.51) RIPK1
SCHEMBL29361216 0.88 RIPK1 (0.47) RIPK1
SCHEMBL24018697 0.85 RIPK1 (0.71) RIPK1
SCHEMBL24018696 0.85 RIPK1 (0.49) RIPK1
SCHEMBL30017778 0.83 RIPK1 (0.76) RIPK1
SCHEMBL18248323 0.83 RIPK1 (0.76) RIPK1
SCHEMBL18255205 0.83 RIPK1 (0.76) RIPK1
SCHEMBL20254437 0.83 RIPK1 (0.56) RIPK1
SCHEMBL24220438 0.82 RIPK1 (0.58) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851433-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2023-12-26 — — US disclosed
US-11851433-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2023-12-26 — — US disclosed
US-11851433-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2023-12-26 — — US disclosed
EP-3625234-B1 HEXAHYDROPYRAZOLO [1,2-A] DIAZEPINONES AND RELATED HETEROCYCLES AS INHIBITORS OF RIP-1 KINASE DENALI THERAPEUTICS INC (US) 2023-09-20 — — EP disclosed
EP-3625234-B1 HEXAHYDROPYRAZOLO [1,2-A] DIAZEPINONES AND RELATED HETEROCYCLES AS INHIBITORS OF RIP-1 KINASE DENALI THERAPEUTICS INC (US) 2023-09-20 — — EP disclosed
US-20220024938-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2022-01-27 — — US disclosed
US-20220024938-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2022-01-27 — — US disclosed
US-11174262-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2021-11-16 — — US disclosed
US-11174262-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2021-11-16 — — US disclosed
CN-110914275-A Compounds, compositions and methods 戴纳立制药公司 2020-03-24 — — CN disclosed
US-20200079784-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2020-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200079784-A1 Compounds, Compositions and Methods BAX, CASP3, CASP8 RIPK1 263/4885
US-20220024938-A1 Compounds, Compositions and Methods BAX, CASP3, CASP8 RIPK1 263/4885
US-11174262-B2 Compounds, compositions and methods BAX, CASP3, CASP8 RIPK1 263/4885
US-11851433-B2 Compounds, compositions and methods BAX, CASP3, CASP8 RIPK1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback